Amarin | AMRN - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.58B 316M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
AstraZeneca USD 5.06B 455M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
DBV Technologies USD 3.63M 3.18M 2025-09
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 151M 21M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03